Nkarta to webcast initial NKX019 data in autoimmune disease at ACR 2026Nov 6PublicationNkarta, Inc.NKX019
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Nkarta reports Q2 2026 results, continued enrollment in autoimmune NK-cell trialsAug 10Quarterly updateNkarta, Inc.